Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Designing Magnetically Responsive Biohybrids Composed of Cord Blood-Derived Natural Killer Cells and Iron Oxide Nanoparticles.

Burga RA, Khan DH, Agrawal N, Bollard CM, Fernandes R.

Bioconjug Chem. 2019 Feb 22. doi: 10.1021/acs.bioconjchem.9b00048. [Epub ahead of print]

PMID:
30779553
2.

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.

Pearson ADJ, Scobie N, Norga K, Ligas F, Chiodin D, Burke A, Minard-Colin V, Adamson P, Marshall LV, Balakumaran A, Benettaib B, Bhargava P, Bollard CM, Bolotin E, Bomken S, Buechner J, Burkhardt B, Caron H, Copland C, Demolis P, Egorov A, Farhan M, Zugmaier G, Gross T, Horton-Taylor D, Klapper W, Lesa G, Marcus R, Miles RR, Nottage K, Pacaud L, Ricafort R, Schrappe M, Sterba J, Vezan R, Weiner S, Kim SY, Reaman G, Vassal G.

Eur J Cancer. 2019 Feb 14;110:74-85. doi: 10.1016/j.ejca.2019.01.013. [Epub ahead of print]

PMID:
30772656
3.

Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease.

Abraham AA, Lang H, Meier ER, Nickel RS, Dean M, Lawal N, Speller-Brown B, Wang Y, Kean L, Bollard CM.

Pediatr Blood Cancer. 2019 Jan 4:e27601. doi: 10.1002/pbc.27601. [Epub ahead of print]

PMID:
30609269
4.

Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders.

Harris KM, Davila BJ, Bollard CM, Keller MD.

J Allergy Clin Immunol Pract. 2018 Dec 20. pii: S2213-2198(18)30721-9. doi: 10.1016/j.jaip.2018.10.049. [Epub ahead of print] Review.

PMID:
30581131
5.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2018 Dec 18. pii: S1083-8791(18)30890-5. doi: 10.1016/j.bbmt.2018.12.068. [Epub ahead of print]

PMID:
30576834
6.

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.

McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM.

Blood. 2018 Nov 29;132(22):2351-2361. doi: 10.1182/blood-2018-07-863654. Epub 2018 Sep 27.

PMID:
30262660
7.

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Sung JA, Patel S, Clohosey ML, Roesch L, Tripic T, Kuruc JD, Archin N, Hanley PJ, Cruz CR, Goonetilleke N, Eron JJ, Rooney CM, Gay CL, Bollard CM, Margolis DM.

Mol Ther. 2018 Oct 3;26(10):2496-2506. doi: 10.1016/j.ymthe.2018.08.015. Epub 2018 Sep 21.

PMID:
30249388
8.

Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma.

Strati P, Patel S, Nastoupil L, Fanale MA, Bollard CM, Lin AY, Gordon LI.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):592-603. doi: 10.1200/EDBK_200549. Review.

PMID:
30231316
9.

β2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans.

Graff RM, Kunz HE, Agha NH, Baker FL, Laughlin M, Bigley AB, Markofski MM, LaVoy EC, Katsanis E, Bond RA, Bollard CM, Simpson RJ.

Brain Behav Immun. 2018 Nov;74:143-153. doi: 10.1016/j.bbi.2018.08.017. Epub 2018 Aug 30.

PMID:
30172948
10.

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy.

Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network.

Nat Rev Clin Oncol. 2019 Jan;16(1):45-63. doi: 10.1038/s41571-018-0075-2. Review.

PMID:
30082906
11.

A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae.

Castillo P, Wright KE, Kontoyiannis DP, Walsh T, Patel S, Chorvinsky E, Bose S, Hazrat Y, Omer B, Albert N, Leen AM, Rooney CM, Bollard CM, Cruz CRY.

Mol Ther Methods Clin Dev. 2018 Mar 14;9:305-312. doi: 10.1016/j.omtm.2018.03.003. eCollection 2018 Jun 15.

12.

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.

Allen CE, Marsh R, Dawson P, Bollard CM, Shenoy S, Roehrs P, Hanna R, Burroughs L, Kean L, Talano JA, Schultz KR, Pai SY, Baker KS, Andolina JR, Stenger EO, Connelly J, Ramirez A, Bryant C, Eapen M, Pulsipher MA.

Blood. 2018 Sep 27;132(13):1438-1451. doi: 10.1182/blood-2018-01-828277. Epub 2018 Jul 11.

PMID:
29997222
13.

Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency.

Miller HK, Hanley PJ, Lang H, Lazarski CA, Chorvinsky EA, McCormack S, Roesch L, Albihani S, Dean M, Hoq F, Adams RH, Bollard CM, Keller MD.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1944-1946. doi: 10.1016/j.bbmt.2018.04.030. Epub 2018 May 9.

PMID:
29753156
14.

Introduction to a review series on emerging immunotherapies for hematologic diseases.

Paczesny S, Pavletic SZ, Bollard CM.

Blood. 2018 Jun 14;131(24):2617-2620. doi: 10.1182/blood-2018-04-840793. Epub 2018 May 4. Review.

15.

HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

Patel S, Chorvinsky E, Albihani S, Cruz CR, Jones RB, Shpall EJ, Margolis DM, Ambinder RF, Bollard CM.

Mol Ther. 2018 Jun 6;26(6):1435-1446. doi: 10.1016/j.ymthe.2018.04.009. Epub 2018 Apr 12.

PMID:
29724686
16.

A single exercise bout augments adenovirus-specific T-cell mobilization and function.

Kunz HE, Spielmann G, Agha NH, O'Connor DP, Bollard CM, Simpson RJ.

Physiol Behav. 2018 Oct 1;194:56-65. doi: 10.1016/j.physbeh.2018.04.035. Epub 2018 Apr 30.

PMID:
29723594
17.

How I treat T-cell chronic active Epstein-Barr virus disease.

Bollard CM, Cohen JI.

Blood. 2018 Jun 28;131(26):2899-2905. doi: 10.1182/blood-2018-03-785931. Epub 2018 Apr 30. Review.

PMID:
29712633
18.

Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.

McLaughlin LP, Bollard CM, Keller MD.

Front Immunol. 2018 Mar 19;9:556. doi: 10.3389/fimmu.2018.00556. eCollection 2018. Review.

19.

Reprint of: Virus-Specific T Cells: Broadening Applicability.

Barrett AJ, Prockop S, Bollard CM.

Biol Blood Marrow Transplant. 2018 Mar;24(3S):S1-S6. doi: 10.1016/j.bbmt.2017.12.787. Review.

PMID:
29425515
20.

Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.

Huang SH, Ren Y, Thomas AS, Chan D, Mueller S, Ward AR, Patel S, Bollard CM, Cruz CR, Karandish S, Truong R, Macedo AB, Bosque A, Kovacs C, Benko E, Piechocka-Trocha A, Wong H, Jeng E, Nixon DF, Ho YC, Siliciano RF, Walker BD, Jones RB.

J Clin Invest. 2018 Feb 1;128(2):876-889. doi: 10.1172/JCI97555. Epub 2018 Jan 22.

21.

Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patients.

McCormack SE, Cruz CRY, Wright KE, Powell AB, Lang H, Trimble C, Keller MD, Fuchs E, Bollard CM.

Cytotherapy. 2018 Mar;20(3):385-393. doi: 10.1016/j.jcyt.2017.11.010. Epub 2018 Jan 10.

PMID:
29331266
22.

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.

Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM.

J Clin Oncol. 2018 Apr 10;36(11):1128-1139. doi: 10.1200/JCO.2017.74.3179. Epub 2018 Jan 9.

PMID:
29315015
23.

Developing T-cell therapies for lymphoma without receptor engineering.

Grant M, Bollard CM.

Blood Adv. 2017 Dec 8;1(26):2579-2590. doi: 10.1182/bloodadvances.2017009886. eCollection 2017 Dec 12. Review.

24.

Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study.

Williams KM, Holter-Chakrabarty J, Lindenberg L, Duong Q, Vesely SK, Nguyen CT, Havlicek JP, Kurdziel K, Gea-Banacloche J, Lin FI, Avila DN, Selby G, Kanakry CG, Li S, Scordino T, Adler S, Bollard CM, Choyke P, Gress RE.

Lancet Haematol. 2018 Jan;5(1):e44-e52. doi: 10.1016/S2352-3026(17)30215-6. Epub 2017 Dec 14.

25.

Developing T-cell therapies for lymphoma without receptor engineering.

Grant M, Bollard CM.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):622-631. doi: 10.1182/asheducation-2017.1.622. Review.

26.

Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

Grant ML, Bollard CM.

Blood Rev. 2018 May;32(3):203-224. doi: 10.1016/j.blre.2017.11.004. Epub 2017 Nov 27. Review.

PMID:
29198753
27.

Introduction to a review series on therapeutic antibodies.

Stevenson FK, Bollard CM.

Blood. 2018 Jan 4;131(1):1. doi: 10.1182/blood-2017-10-798769. Epub 2017 Nov 8. No abstract available.

28.

Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.

Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP.

Br J Haematol. 2017 Dec;179(5):739-747. doi: 10.1111/bjh.14951. Epub 2017 Oct 29.

PMID:
29082519
29.

Virus-Specific T Cells for the Immunocompromised Patient.

Houghtelin A, Bollard CM.

Front Immunol. 2017 Oct 11;8:1272. doi: 10.3389/fimmu.2017.01272. eCollection 2017. Review.

30.

Virus-Specific T Cells: Broadening Applicability.

Barrett AJ, Prockop S, Bollard CM.

Biol Blood Marrow Transplant. 2018 Jan;24(1):13-18. doi: 10.1016/j.bbmt.2017.10.004. Epub 2017 Oct 12. Review.

31.

Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the β2-adrenergic receptor.

Agha NH, Baker FL, Kunz HE, Graff R, Azadan R, Dolan C, Laughlin MS, Hosing C, Markofski MM, Bond RA, Bollard CM, Simpson RJ.

Brain Behav Immun. 2018 Feb;68:66-75. doi: 10.1016/j.bbi.2017.10.001. Epub 2017 Oct 7.

PMID:
29017969
32.

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.

Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B.

J Clin Invest. 2017 Sep 1;127(9):3462-3471. doi: 10.1172/JCI94306. Epub 2017 Aug 14.

33.

Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.

Sung JA, Sholtis K, Kirchherr J, Kuruc JD, Gay CL, Nordstrom JL, Bollard CM, Archin NM, Margolis DM.

EBioMedicine. 2017 Sep;23:52-58. doi: 10.1016/j.ebiom.2017.07.019. Epub 2017 Jul 29.

34.

Engineering cord blood to improve engraftment after cord blood transplant.

Mehta RS, Dave H, Bollard CM, Shpall EJ.

Stem Cell Investig. 2017 May 25;4:41. doi: 10.21037/sci.2017.05.01. eCollection 2017. Review.

35.

Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.

Dave H, Luo M, Blaney JW, Patel S, Barese C, Cruz CR, Shpall EJ, Bollard CM, Hanley PJ.

Mol Ther Methods Clin Dev. 2017 Mar 8;5:13-21. doi: 10.1016/j.omtm.2017.02.001. eCollection 2017 Jun 16.

36.

Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: Lessons from the acute graft versus host disease experience.

Conklin LS, Hanley PJ, Galipeau J, Barrett J, Bollard CM.

Cytotherapy. 2017 Jun;19(6):655-667. doi: 10.1016/j.jcyt.2017.03.006. Epub 2017 Apr 19. Review.

PMID:
28433516
37.

Mobilizing Immune Cells With Exercise for Cancer Immunotherapy.

Simpson RJ, Bigley AB, Agha N, Hanley PJ, Bollard CM.

Exerc Sport Sci Rev. 2017 Jul;45(3):163-172. doi: 10.1249/JES.0000000000000114. Review.

PMID:
28418996
38.

HIV Receives a "One Two Knockout Punch".

Cruz CR, Bollard CM.

Mol Ther. 2017 Mar 1;25(3):566-567. doi: 10.1016/j.ymthe.2017.02.001. Epub 2017 Feb 8. No abstract available.

39.

Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders.

McLaughlin LP, Bollard CM, Keller M.

Curr Allergy Asthma Rep. 2017 Jan;17(1):3. doi: 10.1007/s11882-017-0669-2. Review.

PMID:
28116637
40.

Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.

Yvon ES, Burga R, Powell A, Cruz CR, Fernandes R, Barese C, Nguyen T, Abdel-Baki MS, Bollard CM.

Cytotherapy. 2017 Mar;19(3):408-418. doi: 10.1016/j.jcyt.2016.12.005. Epub 2017 Jan 19.

PMID:
28109751
41.

EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.

McLaughlin LP, Gottschalk S, Rooney CM, Bollard CM.

Methods Mol Biol. 2017;1532:255-265.

PMID:
27873282
42.

Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma.

Cano-Mejia J, Burga RA, Sweeney EE, Fisher JP, Bollard CM, Sandler AD, Cruz CRY, Fernandes R.

Nanomedicine. 2017 Feb;13(2):771-781. doi: 10.1016/j.nano.2016.10.015. Epub 2016 Nov 5.

PMID:
27826115
43.

Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.

McLaughlin LP, Lang H, Williams E, Wright KE, Powell A, Cruz CR, Colberg-Poley AM, Barese C, Hanley PJ, Bollard CM, Keller MD.

Cytotherapy. 2016 Dec;18(12):1515-1524. doi: 10.1016/j.jcyt.2016.08.010. Epub 2016 Sep 28.

44.

Cellular therapy for sickle cell disease.

Abraham A, Jacobsohn DA, Bollard CM.

Cytotherapy. 2016 Nov;18(11):1360-1369. doi: 10.1016/j.jcyt.2016.06.011. Epub 2016 Jul 14. Review.

45.

Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy.

Burga RA, Patel S, Bollard CM, Y Cruz CR, Fernandes R.

Nanomedicine (Lond). 2016 Jul;11(14):1759-67. doi: 10.2217/nnm-2016-0160. Epub 2016 Jul 7.

46.

PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.

St John LS, Wan L, He H, Garber HR, Clise-Dwyer K, Alatrash G, Rezvani K, Shpall EJ, Bollard CM, Ma Q, Molldrem JJ.

Cytotherapy. 2016 Aug;18(8):995-1001. doi: 10.1016/j.jcyt.2016.05.007.

47.

Science, ethics and communication remain essential for the success of cell-based therapies.

Dominici M, Nichols KM, Levine AD, Rasko JE, Forte M, O'Donnell L, Koh MB, Bollard CM, Weiss DJ.

Brain Circ. 2016 Jul-Sep;2(3):146-151. doi: 10.4103/2394-8108.192525. Epub 2016 Oct 18. Review.

48.

T-cell therapies for HIV: Preclinical successes and current clinical strategies.

Patel S, Jones RB, Nixon DF, Bollard CM.

Cytotherapy. 2016 Aug;18(8):931-42. doi: 10.1016/j.jcyt.2016.04.007. Epub 2016 Jun 2. Review.

49.

Introduction to a review series on advances in cell-based immune therapeutics in hematology.

Bollard CM, Stevenson FK.

Blood. 2016 Jun 30;127(26):3293. doi: 10.1182/blood-2016-05-713255. Epub 2016 May 20. No abstract available.

50.

T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Bollard CM, Heslop HE.

Blood. 2016 Jun 30;127(26):3331-40. doi: 10.1182/blood-2016-01-628982. Epub 2016 May 20. Review.

Supplemental Content

Loading ...
Support Center